Coexistence HBsAg/HBcAC, Clinical Characterístics & Outcomes

Last updated: July 5, 2022
Sponsor: Corporacion Parc Tauli
Overall Status: Active - Recruiting

Phase

N/A

Condition

Hepatitis B

Hepatitis

Treatment

N/A

Clinical Study ID

NCT05446532
2022/5032
  • Ages 18-90
  • All Genders

Study Summary

HBV infection is a dynamic process with complex interactions between virus replication and the host's immune response. The appearance of anti-HBs after HBV infection generally indicates recovery and immunity to HBV1 infection. However, there are several published studies that describe the coexistence of the marker of chronic infection (HBsAg +) and the marker of functional cure (HBsAc +). There are contradictory studies on whether the coexistence of HBsAg/HBsAc implies a different clinical course.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • all those patients who have been seen in outpatient hepatology consultations and whopresent positive HBsAg and HBsAc serology simultaneously.

Exclusion

Exclusion Criteria:

  • Hepatitis C or HIV Co-infection

Study Design

Total Participants: 120
Study Start date:
June 15, 2022
Estimated Completion Date:
December 31, 2022

Connect with a study center

  • H. Consorci Sanitari Parc Tauli

    Sabadell, Barcelona
    Spain

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.